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AIM: Sunitinib has shown benefit in patientswith imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However,
its advantages are somewhat diminished because of associated toxicities. Herein, we clarify the efficacy and safety of
fractioned dose regimen of sunitinib by a pharmacokinetic and efficacy study. MATERIALS AND METHODS: Between
2001 andMarch 2013, a total of 214patientswithmetastaticGISTwas treated at ChangGungMemorial Hospital. Among
them, 55 (11.6%) patients who received sunitinib were investigated. One group of patients was administered with
standard dose of once-daily sunitinib (standard dose group) and the other group was administered with standard total
daily dose of sunitinib in fractioned doses (fractioned dose group).RESULTS: Thirty-twomale and 23 female patientswith
amedian age of 55 years received sunitinib. Themedian duration of sunitinib administrationwas 9.2months. The clinical
benefit was 65.2%. Themean peak blood level of sunitinib in patients with fractioned doses was significantly lower than
that in those with once-daily dose (83.4 vs 50.1 ng/ml, P = .01). The rates of adverse effects of hand-foot syndrome,
mucositis, and yellow skin were significantly decreased by fractioned doses of sunitinib. However, the progression-free
andoverall survival didnot differ betweenpatientswithdifferent treatment regimens.CONCLUSION:The fractioneddose
regimen of sunitinib appears to be a safe and effective treatment for patients with IM-resistant/intolerant GISTs.
Significantly decreased toxicity of this regimen could be explained by significantly lower peak sunitinib blood level.
However, the treatment efficacy is not reduced by this regimen.
Translational Oncology (2014) 7, 620–6252These authors contributed equally to this paper.
Received 20 May 2014; Revised 14 August 2014; Accepted 15 August 2014
© 2014 Neoplasia Press, Inc. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1936-5233/14
http://dx.doi.org/10.1016/j.tranon.2014.08.004
Translational Oncology Vol. 7, No. 5, 2014 Chen et al. 621Introduction
Gastrointestinal stromal tumors (GISTs) primarily arise from
mesenchymal tissue in the gastrointestinal (GI) tract and abdomen.
Although GISTs are rare, representing only an estimated 0.1% to 3%
of all GI tract tumors [1], they account for the most common
mesenchymal malignancy of the GI tract [2]. GISTs appear to be
related to the interstitial cells of Cajal [3] and express the cell surface
transmembrane receptor KIT, which has tyrosine kinase activity.
Gain-of-function mutations of KIT are frequent in GISTs and result
in constitutive activation of KIT signaling and lead to uncontrolled
cell proliferation and resistance to apoptosis [4,5]. The KIT tyrosine
kinase inhibitor imatinib (IM) mesylate has shown a promising
clinical result for patients with advanced GIST [6], and several trials
have shown a promising effect of this targeted therapy [6,7]. Our
previous study showed that IM mesylate significantly affected survival
in patients with GIST [8–10]. However, progression of GIST
eventually develops and emerges as a challenge.
Sunitinib is a multitargeted tyrosine kinase inhibitor that
predominantly targets vascular endothelial growth factor receptors
and is used for treatment of metastatic renal cell carcinoma and GIST
[11]. In addition to vascular endothelial growth factor receptors,
sunitinib inhibits other receptor tyrosine kinases, including platelet-
derived growth factor receptors (PDGFRs), KIT, Fms-like tyrosine
kinase-3, colony-stimulating factor 1, and RET, which are involved in
a great variety of malignancies [12]. In GIST, sunitinib is
administered as a second-line targeted therapy, offering a new
treatment option for patients who are refractory to IM. Although
continuous once-daily dosing of sunitinib appears to be a safe and
effective dosing regimen for patients with IM-resistant GIST, several
adverse events (AEs), such as diarrhea, cutaneous toxicity, hyperten-
sion, myelosuppression, and thyroid dysfunction, have been reported
[12]. These drug-related toxicities may reduce the treatment duration
and patient compliance and therefore diminish treatment advantages
of sunitinib. In this study, we investigated the efficacy, safety, and
pharmacokinetics (PK) of administering the total daily dose of
sunitinib in fractioned doses when treating GIST patients with IM
intolerance or failure. The goal was to treat GIST patients with a
regimen that has similar efficacy and a better safety profile.Methods
Patient Population
Between 2001 and March 2013, a total of 214 patients who had
histologically confirmed, recurrent, or metastatic GIST that expressed
CD117 or CD34 was treated at the Department of Medical
Oncology and Surgery in Chang Gung Memorial Hospital in
Taiwan. Failure of prior IM therapy, demonstrated by disease
progression (based on Response Evaluation Criteria in Solid Tumors)
[13] or discontinuation of IM due to toxicity, was one of the inclusion
criteria in this study. Additional eligibility criteria included an Eastern
Cooperative Oncology Group performance status of 0 or 1 and
adequate cardiac, hepatic, renal, coagulation, and hematologic
functions. Key exclusion criteria included lack of recovery from the
acute toxic effects of previous anticancer therapy or IM treatment,
discontinuation of IM therapy within 2 weeks or of any other
approved/investigational drugs for GIST within 4 weeks before
starting sunitinib treatment, clinically significant cardiovascular
events or diseases in the previous 12 months, diabetes mellitus with
clinical evidences of peripheral vascular disease or diabetic ulcers, or adiagnosis of any second malignancy within the previous 5 years.
Patients could have previously received chemotherapeutic regimens
(the last chemotherapy treatment must have been at least 4 weeks
before study entry) and undergone radiotherapy, or surgery, or both.
The study was approved by the local Institutional Review Board of
Chang Gung Memorial Hospital (101-0274C), and a written
informed consent for drug administration and the analysis of
tumor-associated genetic alteration was obtained independently
from each patient.
Study Design and Evaluation of Efficacy and Safety
A retrospective study was conducted to evaluate the effects of
sunitinib in inducing objective responses in Taiwanese GIST
patients. Patients received 50 mg interruptedly (4 weeks on and
2 weeks off) or 37.5 mg continuously of sunitinib in 12.5-mg
capsules taken daily through mouth with food. We classified them
into two groups as follows: one group of patients was administered
with the above regimens once daily (standard dose group, i.e., four
capsules (12.5 mg per capsule) per day, 4 weeks on and 2 weeks off,
or three capsules continuously), and the other group of patients was
administered with the above regimens in fractioned doses (fractioned
dose group, i.e., one capsule (12.5 mg per capsule) four times per day,
4 weeks on and 2 weeks off, or one capsule three times a day
continuously without rest).
The patients received regular physical examinations and evalua-
tions of performance status, body weight, complete blood counts, and
serum chemistries. The administration of each dose and any AEs were
recorded for each patient. Standard computed tomography was
performed on each patient every 3 months in the first 3 years and
every 6 months for the following 2 years to assess patients’ responses.
Measurement of efficacy was based on objective tumor assessments
using Response Evaluation Criteria in Solid Tumors with a minor
modification to allow use of standard radiographic protocols for spiral
computed tomography. Time to response was defined as the interval
from the start of sunitinib treatment to the date of achieving an
objective response (complete response or partial response). Time to
progression was defined as the interval from the start of sunitinib
treatment to the date of reaching disease progression. Progression-free
survival (PFS) was defined as the duration of time between sunitinib
initiation and tumor progression or death from any causes. Overall
survival (OS) was defined as survival after administration of sunitinib,
and death was the endpoint of the study. Response rate, PFS, OS,
time to response, duration of response, and time to progression were
recorded. Safety and tolerability were assessed by analysis of AEs,
physical examinations, vital signs, Eastern Cooperative Oncology
Group performance status, and abnormal laboratory values (for
example, complete blood count with differential, serum electrolyte
measurements, and electrocardiogram). Cardiac function was assessed
at screening, at day 28 of all treatment cycles, and at the end of
treatment with a 12-lead electrocardiogram and multigated acquisi-
tion scans. Toxic effects were recorded in accordance with the
National Cancer Institute Common Toxicity Criteria [14].
PK Analysis of Sunitinib
Blood samples were collected from selected patients in the study for
PK analysis of sunitinib. The blood samples were collected 5 to
6 hours after drug administration to measure the peak levels of
sunitinib. Each 8-ml blood sample was collected into heparinized
polypropylene tubes, centrifuged at 1000g for 10 minutes for plasma
Table 2. PK between Metastatic GIST Patients Receiving Divided and Non-Divided Doses of
Sunitinib
Divided Group (24 Samples
per 12 Patients)
Non-Divided Group (24 Samples
per 12 Patients)
P Value
PK (ng/ml) .01
Mean ± SD 50.1 ± 12.4 83.4 ± 36.8
Range 19.7-64.8 44.3-168.3
Mann-Whitney U test.
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concentrations of sunitinib and CGP74588 were determined by
using a validated liquid chromatography–tandem mass spectrometry
assay. The lower limit of quantification was 4 ng/ml for both
sunitinib and CGP74588.
Analysis of KIT and PDGFRA Mutations
Sections were prepared from formalin-fixed, paraffin-embedded,
pretreated specimens that were trimmed to enrich tumor cells.
Polymerase chain reaction amplification of genomic DNA for KIT
and PDGFRA was performed and amplification was analyzed for
mutations as previously described [15].
Statistical Analysis
All data are presented as percentages of patients or means with SDs.
Pearson Chi-square test and Fisher exact test were used for nominal
variables. Survival rates were calculated and plotted with the Kaplan-
Meier method and compared between groups with a log-rank test. All
statistical analyses were performed using the SPSS computer software
package (version 10.0; SPSS, Chicago, IL). A P value of less than .05
was considered to be statistically significant.Results
Clinical Features
Table 1 summarizes the demographic features of 55 GIST patients
who received sunitinib during the study period. There were 32 male
and 23 female patients with a median age of 55 years old (ranging
from 15 to 88 years). The stomach was the most common site for
GISTs treated with sunitinib (23 patients; 35%), followed by the
jejunum and ileum (15 patients; 22%), duodenum (4 patients), and
the colorectum (6 patients; 13%; Table 1).Table 1. Demographic and Genetic Data of 55 GIST Patients with IM Failure or Intolerance
Treated with Sunitinib
n (%; N = 55)
Age (median/range, years) 55.0/15-88
Gender (M/F) 32/23
Location
Stomach 23 (26.6)
Duodenum 4 (12.5)
Jejunum and ileum 15 (23.4)
Ileum 5 (14.1)
Others 7 (18.8)
Colon-Rectum 6 (4.7)
Tumor recurrence
Liver 22
Loco-regional 19
Both 14
Genetic spectrum 39 (84.4)
Exon 11 24
Deletion mutation
Deletion and insertion mutation
Missense mutation
Exon 9 (insertion mutation) 8
Exon 13 1
No mutation (wild type) 5
PDGFRA (exon 18) 1
Median duration of sunitinib use (months) 9.24
M, male; F, female; PDGFRA, platelet-derived growth factor α.PK Analysis of Sunitinib
The peak plasma level of sunitinib of patients in the standard dose
group was significantly higher than that of patients in the fractioned
dose group (mean, 83.4 vs 50.1 ng/ml; P = .01; Table 2).
Adverse Events
Table 3 listed hematologic and non-hematologic AEs between two
groups of patients. Generally, fractioned doses of sunitinib caused
similar or relatively lower rates of AEs when compared with standard
doses of sunitinib.
In addition, the patients who received fractioned doses of sunitinib
developed significant lower rates of yellow skin discoloration, grade 3/
4 hand-foot skin reaction (HFSR), and mucositis when compared
with those who received standard doses of sunitinib. In the standard
dose group, the most common treatment-related non-hematologic
AEs were HFSR (65%), hypertension (54%), diarrhea (42%), and
mucositis (38%). The most frequent treatment-related grade 3/4
non-hematologic AEs among these patients were HFSR (35%),
hypertension (8%), and anorexia (4%). However, in the fractioned
dose group, the most common treatment-related non-hematologic
AEs were hypertension (59%), diarrhea (52%), HFSR (45%), and GI
bleeding (21%). The most frequent treatment-related grade 3/4 non-Table 3. AEs between Divided and Non-Divided Doses of Sunitinib for Metastatic GIST Patients
Divided Dose
(n = 29; %)
Non-Divided Dose
(n = 26; %)
P Value
All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4
Hematologic
Anemia 17 (58.62) 9 (31.03) 16 (61.54) 5 (19.23) .823 .315
Leukopenia 17 (58.62) 2 (6.90) 15 (57.69) 3 (11.54) 1.0 .659
Neutropenia 14 (48.28) 3 (10.34) 12 (46.15) 3 (11.54) .888 1.0
Thrombocytopenia 16 (55.17) 3 (10.34) 15 (57.69) 1 (3.85) .841 .613
Non-hematologic
Anorexia 4 (13.79) 2 (6.90) 6 (23.08) 1 (3.85) .490 1.0
Nausea 2 (6.90) 0 (0) 2 (7.69) 0 (0) 1.0 1.0
Vomiting 2 (6.90) 0 (0) 3 (11.54) 1 (3.85) .659 .473
Diarrhea 15 (51.72) 1 (3.45) 11 (42.31) 0 (0) .484 1.0
Constipation 0 (0) 0 (0) 2 (7.69) 0 (0) .219 1.0
Alopecia 2 (6.90) 0 (0) 1 (3.85) 0 (0) 1.0 1.0
Yellow skin 2 (6.90) 0 (0) 9 (34.62) 0 (0) .017 1.0
HFSR 13 (44.83) 3 (10.34) 17 (65.38) 9 (34.62) .177 .030
Mucositis 1 (3.45) 0 (0) 10 (38.46) 0 (0) .002 1.0
Fever 1 (3.45) 0 (0) 2 (7.69) 1 (3.85) .589 .473
Fatigue 4 (13.79) 1 (3.45) 9 (34.62) 0 (0) .111 1.0
Insomnia 0 (0) 0 (0) 2 (7.69) 0 (0) .219 1.0
AST/ALT 3 (10.34) 1 (3.45) 0 (0) 0 (0) .238 1.0
HTN 17 (58.62) 1 (3.45) 14 (53.85) 2 (7.69) .718 .598
GI bleeding 6 (20.69) 5 (17.24) 1 (3.85) 1 (3.85) .105 .197
Jaundice 0 (0) 0 (0) 0 (0) 0 (0) 1.0 1.0
Creatinine 2 (6.90) 0 (0) 4 (15.38) 0 (0) .406 1.0
Thyroid function 1 (3.45) 0 (0) 1 (3.85) 0 (0) 1.0 1.0
AST/ALT, aspartate aminotransferase/alanine aminotransferase; HTN, hypertension.
Median: 22.6 months
(95%CI: 2.5 – 42.7 )
Figure 2. OS of all patients after initiation of sunitinib.
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HFSR (10%), anorexia (7%), and diarrhea (3%). Not only the
distribution patterns of AEs were slightly different between the two
groups, but the occurrences were also a little different.
The hematologic abnormalities among patients who received
sunitinib in standard doses and in fractioned doses included reduced
levels of hemoglobin (62% and 59%), leukocytes (58% and 59%),
and platelets (58% and 55%), respectively.
Spectrum of Mutations
Tumor specimens suitable for genetic analysis were available from
39 (70.9%) of the 55 GIST patients with IM failure or intolerance.
Overall, 32 (85.7%) of the 39 examined GISTs had activated
mutations of KIT exons 9 and 11. Eight of 39 (20.5%) GISTs had
exon 9 mutation, 24 (61.5%) had exon 11 mutation, and 5 (12.8%)
had no mutation of KIT. One PDGFRA exon 18 mutation was
found. One patient had concurrent deletion mutation in exon 11 and
missense mutation in exon 13; however, the exon 13 mutation was
followed by the deletion mutation in exon 11. This patient developed
acquired resistance and expired from disease progression. All eight
GISTs that had KIT exon 9 mutation displayed in-frame duplication
of nucleotides, resulting in insertion of alanine (A) and tyrosine (Y) at
codons 502 and 503. The KIT exon 11 mutations in the 24 GIST
patients included insertion and deletion mutations, deletion
mutations, and missense mutations.
Treatment Outcomes
The median follow-up time after initiation of sunitinib was
9.2 months. Overall, 1 patient (1.8%) had a complete response, 20
(36.4%) had partial responses, 13 had stable diseases (23.6 %), and
21 had progressive diseases (38.2%). A clinical benefit was observed
in 61.8% of GIST patients. During the median 9.2-month follow-up
after sunitinib use, the median PFS and OS of these 55 GIST patients
were 9.5 and 22.6 months, respectively (Figures 1 and 2). The
median PFS for the 29 patients who were in the fractioned dose groupMedian: 9.5 months
(95%CI: 4.3 – 14.7 )
Figure 1. PFS of all patients after initiation of sunitinib.was 11.7 months, which is similar to the median PFS of 8.3 months
for the 26 patients in the standard dose group (P = .664; Figure 3). At
the same time, the median OS was 20.1 months for the 29 patientsFractioned Standard
N 29 26
Median 11.7 8.3
95%CI 7.1-16.4 2.5-14.0
Log-rank test p=0.664
Standard
Fractioned
Figure 3. PFS of two groups after initiation of sunitinib.
624 Chen et al. Translational Oncology Vol. 7, No. 5, 2014who were in the fractioned dose group and 38.9 months for the 26
patients who were in the standard dose group, which also did not
reach statistical significance (P = .439; Figure 4).
Discussion
This study provided a novel alternative dosing schedule of sunitinib to
treat IM-resistant/intolerant GIST patients. We demonstrated a
clinical response rate of 38.2% for all patients treated with sunitinib
and a median duration of response of 9.5 months. This is similar to
the response rate and slightly higher duration of response to the
results in the previous phase III trial of sunitinib for treatment of
advanced GIST after IM failure [16], which reported a response rate
of 30% and a response duration of 27.3 weeks. The median duration
of response of 9.5 months is also slightly longer than that seen in
another sunitinib treatment experience, which was a global open-label
study that provided sunitinib access to patients with advanced IM
resistant/intolerant GIST. That study reported 8.3 months of PFS in
all intention-to-treat population of 1124 patients [17].
The standard once-daily sunitinib regimen resulted in median PFS
of 8.3 months and median OS of 38.9 months. However, the
fractioned dose regimen of sunitinib led to median PFS of
11.7 months and median OS of 20.1 months. Although no
statistically significant differences were found, the fractioned dose
regimen achieved even longer PFS for these GIST patients who were
resistant or intolerant to IM. The results suggested that sunitinib
treatment either as standard regimen or as fractioned dose regimenStandard
Fractioned
Fractioned Standard
N 29 26
Median 20.1 38.9
95%CI 10.8-29.4 6.5-71.2
Log-rank test p=0.439
Figure 4. OS of two groups after initiation of sunitinib.have similar efficacy. The fractioned doses of sunitinib did not
compromise the clinical effects for GIST patients.
The most important reason for using fractioned doses of sunitinib
was the hope of decreasing occurrence of AEs. The study
demonstrated that fractioned doses of sunitinib caused similar or
relatively lower rates of AEs when compared with standard doses of
sunitinib. Sunitinib in fractioned dose regimen exhibited an
improved safety profile when compared with the standard dose
regimen, especially in all grades of mucositis and yellow skin
discoloration and grade 3/4 of HFSR. These improvements of AEs
grading in divided dose regimen may help GIST patients to continue
sunitinib treatment with or without dosing interruption and/or
dose reduction.
Our previous study demonstrated that sunitinib treatment made the
skin more susceptible to physical damage and such injury was associated
with increased expression of FasL in keratinocytes [18]. We observed
higher plasma levels of sunitinib in patients who developed high-grade
HFSR than in patients without HFSR. The induction of keratinocyte
FasL/Fas in our animal experiments and HFSR patients may result from
the combined effects of sunitinib toxicity and physical pressures.
Therefore, the lower peak plasma levels of sunitinib resulted from the
fractioned doses of sunitinib may partly explain the lower incidence of
grade 3/4 HFSR and other AEs [18].
In conclusion, fractioned dose regimen of sunitinib appears to be a
safe and effective treatment for patients with IM-resistant/intolerant
GISTs. Significantly decreased toxicity of this regimen could be
explained by significantly lower peak sunitinib blood level. The
treatment efficacy is not reduced by this regimen; however, a more
comprehensive study is still warranted due to limited case numbers.References
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